216 related articles for article (PubMed ID: 22571785)
1. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases.
Andrés JI; De Angelis M; Alcázar J; Celen S; Bormans G
Curr Top Med Chem; 2012; 12(11):1224-36. PubMed ID: 22571785
[TBL] [Abstract][Full Text] [Related]
2. Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.
Schröder S; Scheunemann M; Wenzel B; Brust P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917199
[TBL] [Abstract][Full Text] [Related]
3. Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012.
Schröder S; Wenzel B; Deuther-Conrad W; Scheunemann M; Brust P
Molecules; 2016 May; 21(5):. PubMed ID: 27213312
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of phosphodiesterase as cancer therapeutics.
Peng T; Gong J; Jin Y; Zhou Y; Tong R; Wei X; Bai L; Shi J
Eur J Med Chem; 2018 Apr; 150():742-756. PubMed ID: 29574203
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Discovery of PDEs Inhibitors.
Li L; Chen W; Chen T; Ren J; Xu Y
Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
[TBL] [Abstract][Full Text] [Related]
6. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
7. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
9. The role of phosphodiesterases in schizophrenia : therapeutic implications.
Siuciak JA
CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
12. Development of a series of novel carbon-11 labeled PDE10A inhibitors.
Stepanov V; Miura S; Takano A; Amini N; Nakao R; Hasui T; Nakashima K; Taniguchi T; Kimura H; Kuroita T; Halldin C
J Labelled Comp Radiopharm; 2015 May; 58(5):202-8. PubMed ID: 25891816
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.
Andrés JI; De Angelis M; Alcázar J; Iturrino L; Langlois X; Dedeurwaerdere S; Lenaerts I; Vanhoof G; Celen S; Bormans G
J Med Chem; 2011 Aug; 54(16):5820-35. PubMed ID: 21777010
[TBL] [Abstract][Full Text] [Related]
14. Protein-Protein Interactions of Phosphodiesterases.
Al-Nema MY; Gaurav A
Curr Top Med Chem; 2019; 19(7):555-564. PubMed ID: 30931862
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
17. Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4.
Parker CA; Matthews JC; Gunn RN; Martarello L; Cunningham VJ; Dommett D; Knibb ST; Bender D; Jakobsen S; Brown J; Gee AD
Synapse; 2005 Mar; 55(4):270-9. PubMed ID: 15668983
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
19. Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors.
Palacios JM; Beleta J; Segarra V
Farmaco; 1995 Dec; 50(12):819-27. PubMed ID: 8634072
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
